Veraart JKE
Department of Psychiatry, University Medical Centre Groningen, Groningen, the Netherlands; Department of Mood Disorders, PsyQ Haaglanden, Parnassia Psychiatric Institute, The Hague, the Netherlands.
ArticleKetamine
Serum brain-derived neurotrophic factor following oral esketamine in treatment-resistant depression: Results from a randomized placebo-controlled trial.
ArticleKetamine
Predicting changes in depressive symptomatology following oral esketamine treatment in treatment-resistant depression: A machine-learning approach.
ArticleKetamine
A call for the systematic assessment of sexual adverse events in ketamine and esketamine trials and clinical practice.
ArticleKetamine
The role of cytochrome P450 polymorphisms in the pharmacokinetics of oral esketamine.
ArticleKetamine
ATP-binding cassette transporter polymorphisms and the pharmacokinetics of oral esketamine.
ArticleKetamine
Auto-Induction in Oral Esketamine Treatment for Treatment-Resistant Depression: An Exploratory Study.
ArticleKetamine
Plasma esketamine and noresketamine levels and antidepressant response with oral esketamine treatment.
ArticleKetamine
Oral Esketamine as Alternative for Maintenance Electroconvulsive Therapy in Patients With Treatment-Resistant Depression: A Case Series.
ArticleKetamine
Demographic and clinical predictors of response and remission in the treatment of major depressive disorder with ketamine and esketamine: A systematic review.
ArticleKetamine
Oral esketamine in patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial with open-label extension.
ArticleKetamine
Repeated oral esketamine in patients with treatment resistant depression and comorbid posttraumatic stress disorder.
ArticleKetamine
Repeated oral esketamine in patients with treatment resistant depression and comorbid posttraumatic stress disorder
ArticlePsilocybin